Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Daxor Corp DXR

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific... see more

Recent & Breaking News (NDAQ:DXR)

New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

GlobeNewswire April 16, 2024

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING'24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100(TM))

GlobeNewswire April 15, 2024

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

GlobeNewswire April 10, 2024

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

GlobeNewswire April 1, 2024

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

GlobeNewswire March 25, 2024

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

GlobeNewswire March 22, 2024

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

GlobeNewswire March 18, 2024

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire March 18, 2024

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

GlobeNewswire March 11, 2024

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

GlobeNewswire March 8, 2024

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

GlobeNewswire February 26, 2024

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

GlobeNewswire February 12, 2024

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts

GlobeNewswire February 7, 2024

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

GlobeNewswire January 29, 2024

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress

GlobeNewswire January 16, 2024

DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES

GlobeNewswire January 9, 2024

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

GlobeNewswire January 2, 2024

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients

GlobeNewswire November 13, 2023

Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume

GlobeNewswire November 9, 2023

Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

GlobeNewswire October 13, 2023